Patients with metastatic colorectal cancer (CRC) harboring a subset of non-V600 mutations in the BRAF gene were more likely to respond to anti-epidermal growth factor receptor (EGFR) treatment, according to a study published in Clinical Cancer Research.
Class 3 BRAF mutations see better response
Researchers conducted a multicenter pooled analysis of 44 consecutive patients with non-V600 BRAF-mutated metastatic CRC that was identified between 2010 and 2017. Non-V600 BRAF mutations were categorized as activating and RAS-independent (class 2; n=12) or kinase-impaired and RAS-dependent (class 3; n=28).
Only one patient (response rate, 8%) with class 2 BRAF metastatic CRC responded to anti-EGFR treatment, but 14 patients (response rate, 50%) with class 3 BRAF responded (P=0.02).
Among patients with class 3 BRAF mutations, anti-EGFR as first- or second-line therapy induced responses in seven patients (78%). In the third- or later-line setting, seven patients with class 3 BRAF mutations (37%) responded.
“Patients with CRC with class 3 BRAF mutations should be considered for anti-EGFR antibody treatment,” the researchers concluded.